Clinical observation on postoperative analgesia of anesthetized dose of esmketamine in the treatment of adult obstructive sleep apnea syndrome

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042678

Enrollment

Unknown

Registered

2021-01-26

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adult obstructive sleep apnea syndrome

Interventions

experimental group:0.35 mg / kg esmketamine is injected intravenously 5 min after anesthesia induction

control group:The same dose of normal saline was injected after anesthesia induction

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eighty adult patients with obstructive sleep apnea syndrome, ASA I - III, aged 18-65 years, BMI 20-35Kg/m2, scheduled for elective surgery under general anesthesia.

Exclusion criteria

Exclusion criteria: The following patients were not included in this study: Patients with severe cardiovascular and cerebrovascular diseases, heart block disease, liver and kidney dysfunction and neuropsychiatric diseases; pregnancy, lactation or recent pregnancy preparation; contraindications to drugs used in the experiment, cognitive impairment, and inability to cooperate with normal experiments.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale/Score;Ramsay score;Incidence of respiratory depression;Incidence of hallucinations;Total dose of butorphanol;	—

Secondary

Measure	Time frame
The incidence of postoperative nausea, vomiting and other adverse reactions;	—

Countries

China

Contacts

Public ContactBi Congjie

Dalian Municipal Central Hospital Affiliated of Dalian Medical University

bcj0411@126.com+86 13504251513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026